In tumor-bearing mice, the depletion of Tregs during neoadjuvant immune checkpoint blockade (ICB) not only reshapes the intratumoral immune landscape to favor an ICB response but also induces profound and sustained changes in systemic immunity, which are characterized by increased CD8+ T and NK cells and sustained T cell activation after treatment cessation 122. The gene discussed is CD8A; the disease is neoplasm.